These findings align with those of Xin et al., who reported that treatment with a PI3K/AKT/mTOR inhibitor combined with imatinib-enhanced autophagy, while dysregulating CML proliferation [56]. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.